DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: These interesting results confirmed the selectivity of IL-VX in CML patients, offering the possibility to eradicate residual CD26+ LSCs and establish the drug concentration necessary to induce apoptosis [58].